Bioresorbable Coronary Stents Market Size, Share & Trends Analysis Report By Material (Polymer, Metal), By Drug (Sirolimus, Novalimus), By End Use (Outpatient, Inpatient Facilities), By Region, And Segment Forecasts, 2025 - 2030
Bioresorbable Coronary Stents Market Size, Share & Trends Analysis Report By Material (Polymer, Metal), By Drug (Sirolimus, Novalimus), By End Use (Outpatient, Inpatient Facilities), By Region, And Segment Forecasts, 2025 - 2030
The global bioresorbable coronary stents market size is expected to reach USD 210.1 million by 2030, expanding at a CAGR of 4.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. better device attributes of second-generation coronary stents will provide the ascending push to this market.
Bioresorbable stents are intended majorly for the young adult population, whereby these individuals are enabled with a normal functioning artery following complete resorption of the dissolvable devices.Lifestyle diseases and prevalence of associated risk factors underpin the growth in atherosclerosis-related cardiac events. This drives the global disease prevalence in young adults as well as the high volume of elective Percutaneous Coronary Interventions (PCI).
What sets the second-generation bioresorbable coronary stents apart? - Learning from past mistakes, manufacturers have developed new generation bioresorbable with thinner strut thicknesses, faster resorption times, and better radial force. Amaranth, with a single-minded focus on strut thickness, has developed three such devices. Each with a thinner strut. The latest, Magnitude boasts of 100 microns.
Another factor providing a fillip to this market is the less-invasive nature of PCIs as compared to coronary artery bypass grafting, resulting in their high elective procedure volume. In most parts of the world, lack of auditing to check inappropriate surgeries drives the number of coronary stenting procedures. Hence, this market is expected to witness growth due to the high volume of elective PCI, particularly in APAC and Europe.
The polymer segment held the largest market share of 50.2% in 2024 and the metal segment is anticipated to grow at the fastest CAGR over the forecast period.
The sirolimus segment held the largest market share of 63.1% in 2024 and the Novalimus segment is anticipated to grow at the fastest CAGR from 2025 to 2030.
The outpatient facilities segment held the largest market share of 61.9% in 2024 and is anticipated to grow at the fastest CAGR over the forecast period.
Strategic efforts undertaken by the companies to gain a higher market share center on bioresorbable coronary stents development. Companies targeting the clinical pipeline have developed second-generation bioresorbable products with better design specifications, such as devices with thinner strut thicknesses and faster absorption rates that gain comparability with the gold standard, drug-eluting metallic stents.
Please note The report will be delivered in 2-3 business days upon order notification.